ArticleCancer medicine2019
LRP8 is overexpressed in estrogen-negative breast cancers and a potential target for these tumors.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Wnt signaling promotes inflammation and EMT-associated gene expression in mesenchymal TNBC.Scientific reports · 2026Article
- The regulation of LRPs by miRNAs in cancer: influencing cancer characteristics and responses to treatment.Cancer cell international · 2025Review
- Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cells.Journal of hematology & oncology · 2025Article
- MiR-378a-5p exerts a radiosensitizing effect on CRC through LRP8/β-catenin axis.Cancer biology & therapy · 2024Article
- A Novel Methylation-based Model for Prognostic Prediction in Lung Adenocarcinoma.Current genomics · 2024Article
- Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers.Breast cancer (Dove Medical Press) · 2023Article
- Article
- Low-Density Lipoprotein Receptor-Related Protein 8 at the Crossroad between Cancer and Neurodegeneration.International journal of molecular sciences · 2022Review
- Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability.Nature chemical biology · 2022Article
- In silico recognition of a prognostic signature in basal-like breast cancer patients.PloS one · 2022Article
- miR-362-3p suppresses ovarian cancer by inhibiting LRP8.Translational oncology · 2022Article
- miR-30b-5p inhibits cancer progression and enhances cisplatin sensitivity in lung cancer through targeting LRP8.Apoptosis : an international journal on programmed cell death · 2021Article
- Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer.World journal of clinical oncology · 2020Review
- Article
- Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers.Theranostics · 2020Observational
- Contribution of the Low-Density Lipoprotein Receptor Family to Breast Cancer Progression.Frontiers in oncology · 2020Review
- LRP8 is overexpressed in estrogen-negative breast cancers and a potential target for these tumors.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Triple-negative breast cancer (TNBC) is the breast cancer subtype with the worst prognosis. New treatments improving the survival of TNBC patients are, therefore, urgently required. We performed a transcriptome microarray analysis to identify new treatment targets for TNBC. We found that low-density lipoprotein receptor-related protein 8 (LRP8) was more strongly expressed in estrogen receptor-negative breast tumors, including TNBCs and those overexpressing HER2, than in luminal breast tumors and normal breast tissues. LRP8 depletion decreased cell proliferation more efficiently in estrogen receptor-negative breast cancer cell lines: TNBC and HER2 overexpressing cell lines. We next focused on TNBC cells for which targeted therapies are not available. LRP8 depletion induced an arrest of the cell cycle progression in G1 phase and programmed cell death. We also found that LRP8 is required for anchorage-independent growth in vitro, and that its depletion in vivo slowed tumor growth in a xenograft model. Our findings suggest that new approaches targeting LRP8 may constitute promising treatments for hormone-negative breast cancers, those overexpressing HER2 and TNBCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.